Tuesday, 17 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Regulatory Approval

Veradermics Shares Skyrocket 30% in 7 Days Since Phase 3 Goals Hit with 36.4 Hair Count Increase

Veradermics Hits Phase 3 Goals with 36.4 Hair Count Increase for VDPHL01

+30.10% in 7 days $108.82 when we broke this story → $141.57 at 10:44 AM ET, 28 Oct 2026

Veradermics announced that its Phase 3 '304' trial for VDPHL01 met all primary and secondary endpoints with high statistical significance. The results demonstrate significant increases in hair count and support a potential FDA submission for a novel non-hormonal oral treatment.

Veradermics Shares Skyrocket 30% in 7 Days Since Phase 3 Goals Hit with 36.4 Hair Count Increase
Veradermics, Inc · Healthcare · Representative image

Key highlights

  • VDPHL01 achieved a mean increase of 36.4 hairs/cm² in the twice-daily dose group versus 6.6 hairs/cm² for placebo
  • Statistically significant hair growth was observed as early as Month 2, the earliest time point measured
  • Patient-reported outcomes showed 68.7% of participants in the BID arm achieved improved or much improved hair coverage
  • The clinical trial database now includes over 1,000 participants across two successful registration-directed studies
  • Safety data showed no treatment-related serious adverse events or adverse events of cardiac origin

Phase 3 Trial Performance

Veradermics reported that its Study ‘304’ evaluating VDPHL01, a proprietary extended-release oral minoxidil formulation, reached its primary endpoints at Month 6. The trial enrolled 536 male patients with mild-to-moderate pattern hair loss across three arms: once-daily 8.5mg, twice-daily 8.5mg, and placebo. Both active arms showed superior hair growth compared to placebo with a p-value of less than 0.0001. Specifically, non-vellus Target Area Hair Count increases reached 28.6 hairs/cm² for the once-daily group and 36.4 hairs/cm² for the twice-daily group. Statistical separation from placebo was established at the earliest measurement point in Month 2, indicating rapid therapeutic onset.

Clinical and Regulatory Significance

  • The data represents the full placebo-controlled set required to support an FDA New Drug Application for VDPHL01
  • VDPHL01 is positioned to be the first non-hormonal oral therapeutic for pattern hair loss in nearly 30 years
  • Consistency across Study ‘304’ and the previous Study ‘302’ reinforces the efficacy profile of the extended-release formulation
  • Absence of cardiac-origin adverse events addresses a primary safety concern associated with traditional oral minoxidil use
  • Total registration-directed data now covers over 1,000 participants across the clinical program

Business and Pipeline Overview

Based in New Haven, Connecticut, Veradermics is a late-stage biopharmaceutical firm specializing in dermatological treatments. The company’s flagship pipeline candidate, VDPHL01, utilizes a novel delivery system for minoxidil to improve the clinical profile for androgenetic alopecia. Beyond its lead program in male pattern hair loss, the company is advancing a registration-directed Phase 2/3 Study ‘306’ for female pattern hair loss, with results anticipated in the first half of 2027. Veradermics transitioned to the public markets in February 2026 and currently operates as an emerging growth company without commercial product revenue or an order backlog.

Financial Position and Market Context

Veradermics maintains a robust liquidity position following its initial public offering and a subsequent $414.4 million capital raise in April 2026. As of August 2026, the company reported cash, cash equivalents, and marketable securities totaling $819.9 million. Management expects these reserves to fund operations and capital expenditures into 2030. The company’s market capitalization sits at approximately $4.55 billion, though the stock has seen a 16.87% decline over the past week leading up to this announcement. Future financial performance remains closely tied to the upcoming FDA submission timeline and potential commercial launch in the U.S. market.

Veradermics, Inc share price · last month
Line chart of Veradermics, Inc's share price over the last month, from $122.28 on 19 Oct → $128.05 on 16 Nov; our story on 19 Oct at $108.82.

Up 17.7% since our story on 19 Oct: $108.82 when we broke it → $128.05 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
19 Oct$122.28
20 Oct$127.11
21 Oct$136.66
22 Oct$138.49
23 Oct$138.78
26 Oct$137.39
27 Oct$140.72
28 Oct$143.83
29 Oct$143.85
30 Oct$139.69
2 Nov$129.53
3 Nov$133.61
4 Nov$136.51
5 Nov$128.60
6 Nov$138.78
9 Nov$143.95
10 Nov$148.44
11 Nov$156.56
12 Nov$135.29
13 Nov$129.66
16 Nov$128.05
Earlier announcements by Veradermics, Inc
DateAnnouncementAmount
11 Aug 2026Financial results for second quarter 2026 and clinical pipeline updatesSource: SEC filing–
15 Jul 2026Positive topline results from Phase 2 Study '207' of VDPHL01 in female pattern hair lossSource: SEC filing–
29 Apr 2026Pricing of upsized public offering and concurrent private placementSource: SEC filing$414.4 Million
27 Apr 2026Positive topline results from Phase 2/3 Study '302' of VDPHL01 in male pattern hair lossSource: SEC filing–
03 Feb 2026Pricing of upsized initial public offering (IPO) on the NYSESource: pharmexec.com$256.3 Million
Veradermics, Inc · financial snapshot
Share price$108.82
Market cap$4.5B
1-month price change+6.25%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Veradermics, Incorporated announcing positive topline data from its Phase 3 clinical trial of VDPHL01.

Read the filing ↗

Track Veradermics, Inc live

Get the next Veradermics, Inc SEC filing seconds after it lands.

More in Approvals

All →

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.